Dr. Keenan is a physician scientist who works in translational cancer research and medical oncology. Her research interests are in studying the mechanisms of response and resistance to immunotherapy, with a focus on gastrointestinal cancers. Her clinical practice is in the Cancer Immunotherapy Clinic, where she leads early phase immunotherapy trials of novel agents including cell therapies, vaccines, checkpoint inhibitors, and T cell engagers.

The Crouch lab has expertise in the stages of vascular cell development in the human and mouse CNS.�

The Javid Lab's research includes study of protective human humoral responses to tuberculosis, as well as molecular mechanisms by which Mycobacterium tuberculosis adapts and evades host immunity. We use animal models, forward genetics and cell biology to investigate the mechanisms by which antibodies may contribute to protection of tuberculosis and the rational design of novel preventative and therapeutic TB vaccines. Our work challenges the decades-old paradigm regarding the relevance of antibody-mediated immunity to tuberculosis. Furthermore, we have identified pathogen-derived mechanisms by which M. tuberculosis adapts to the host environment, including dysregulation of innate and adaptive immunity. Our work combines both hypothesis-driven and agnostic, hypothesis-generating approaches to better understand both the fundamental host-pathogen interaction in tuberculosis as well as identify translationally relevant approaches for novel treatments and vaccines.

The Peterlin Lab uses molecular biology, immunology, virology and genetics to tackle intractable immunodeficiencies, be they the bare lymphocyte syndrome or AIDS. These approaches also find resonance in autoimmunity and cancer. In the process, these diseases and their pathogens educate us about human biology and evolution. Indeed, new paradigms in genomic stability, transcription, transport and intracellular traffic have been forthcoming from these studies. Our ultimate goals are to use this knowledge of basic molecular mechanisms to cure human diseases.

The Ma Lab studies the molecular and cellular mechanisms underlying inflammation and cancer. We have focused upon a subset of ubiquitin regulating proteins that play dominant roles in prevent inflammation and cancer. A20 and several biochemically related binding partners are potent regulators of ubiquitination and disease. These proteins exert several biochemical functions to (1) prevent inflammatory diseases and cancer in human patients; (2) prevent inflammation and cancer in mice; (3) restrict NF���������B signaling and immune cell activation; (4) restrict inflammasome activation; (5) prevent multiple forms of cell death; and (6) preserve tissue integrity. Patients born with haploinsufficient A20 genes develop early onset inflammatory diseases. Ongoing studies utilize genetic engineering, cell signaling, and mass spectrometry techniques to unravel the mechanisms by which A20 and related proteins regulate ubiquitin dependent signals and tissue homeostasis. We have recently generated a serieo dissect the biochemical mechanisms by which A20 performs these critical functions. Translational research in the laboratory seeks to align insights from biochemical and mouse based biology with the biology of human peripheral blood cells and intestinal tissues. These efforts should improve our understanding of human disease subtypes and ultimately develop novel approaches of treating inflammatory and malignant diseases.

The Butte Lab���������s interest lies in harnessing the publicly accessible clinical trials and research data to gain a systemic understanding of the immune system at the patient level. As an example, we have successfully shown that reanalysis of Rituximab therapy in ANCA-Associated Vasculitis identified granulocyte subsets as a novel early marker of successful treatment in stratified patients. The lab is also leveraging EMR data to develop prediction models for recruiting potential cl

The Wiita Lab focuses on the development of novel cancer immunotherapies. To do this, we aim to integrate our expertise in mass spectrometry-based proteomics, chemical biology, protein engineering, cellular engineering, and preclinical modeling. We have a primary interest in these therapies for the treatment of hematologic cancers spanning myeloid, lymphoid, and plasma cell malignancies.�

The Prakash Lab studies the immunobiology of lung injury - both sterile and infectious - and investigates lung cellular and molecular signaling contributions as well as the immuno-metabolic influence of the microbiome on the lung.

The Weiss Lab is interested in understanding how receptors involved in antigen recognition can initiate signal transduction events that regulate cell responses in the immune system. We know that receptors involved in antigen recognition functionally interact with tyrosine kinases and phosphatases, enzymes that regulate protein phosphorylation, to induce signaling pathways that regulate cellular responses and gene expression. We are using genetically selective small molecule inhibitors of kinases together with phosphatase mutants to study how thresholds for the initiation of immune responses are set and how feedback circuits influence responses. We would like to understand how the tyrosine kinases and phosphatases in these pathways are regulated and how they control cellular responses in development, in normal immune responses and in autoimmune diseases such as lupus and rheumatoid arthritis.

The Prather Lab focuses on the influence of psychological and behavioral factors on immune function in humans. Much of this work has focused the effects of insufficient sleep (measured in lab using sleep deprivation protocols and in the field) on inflammatory functioning and susceptibility to infectious illness, as well as on the impacts of acute and chronic psychological stress on markers of immunological aging.

The Molofsky Lab's goals are to understand the function and regulation of tissue resident lymphocytes in settings of tissue development, remodeling, infection, and pathology while providing a strong and supportive environment for our research trainees. By understanding the physiologic roles of tissue-resident immune cells and their regulation, we hope to define novel pathways that can be targeted in diverse human disease, including obesity/type 2 diabetes, allergic pathologies (asthma, allergy, atopic dermatitis), and neuropsychiatric disease. We are focused on type-2 immune-associated lymphocytes, including group 2 innate lymphoid cells (ILC2) and subsets of regulatory T (Treg) cells, and the ���������niche��������� signals involved in their regulation. These recently appreciated tissue resident cells are early organizers of tissue remodeling and first responders during tissue damage and infection, positioning the

The Molofsky Lab's goals are to understand the function of tissue resident lymphocytes.

The Shum Lab's research lies at the intersection of autoimmunity and pulmonary disease.